An article by the (AP) published Oct. 17 considers, “Are 3D mammograms better than standard 2D imaging for catching advanced [breast] cancers?” The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), discussed in the article and managed daily by the 黑料网® (黑料网®) Center for Research and Innovation, intends to find out.
— one of the most diverse cancer screening trials in history — already has nearly 93,000 of the planned 128,000 participants enrolled. The AP reports, “At the U.S. study sites, 21% of study participants are Black women — that’s higher than a typical cancer treatment study, in which 9% of participants are Black.”
The AP quotes Etta Pisano, MD, F黑料网, 黑料网 Chief Research Officer, who shared that the study, led by the ECOG-黑料网IN Cancer Research Group, “added more international sites to enhance the trial’s diversity, particularly for Hispanic and Asian women.”
For more information, visit .